Quantum Biopharma Files 6-K, Incorporates Press Release
Ticker: QNTM · Form: 6-K · Filed: Aug 30, 2024 · CIK: 1771885
| Field | Detail |
|---|---|
| Company | Quantum Biopharma Ltd. (QNTM) |
| Form Type | 6-K |
| Filed Date | Aug 30, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing-update, registration-statement, corporate-action
TL;DR
Quantum Biopharma (fka FSD Pharma) filed a 6-K on Aug 30, incorporating an Aug 29 press release into their F-3 registration. Watch for updates.
AI Summary
Quantum Biopharma Ltd. (formerly FSD Pharma Inc.) filed a Form 6-K on August 30, 2024, incorporating by reference a press release issued on August 29, 2024. This filing is related to their Registration Statement on Form F-3 (SEC File No. 333-276264). The company is incorporated in A6 and its fiscal year ends on December 31.
Why It Matters
This filing indicates ongoing reporting activity and potential updates related to Quantum Biopharma's securities offerings or other material information previously filed with the SEC.
Risk Assessment
Risk Level: medium — The filing itself is routine, but its incorporation into a Form F-3 registration statement suggests potential ongoing capital raising or significant corporate actions that could impact the stock.
Key Numbers
- 001-39152 — SEC File Number (Quantum Biopharma Ltd.'s primary SEC filing number.)
- 333-276264 — Form F-3 SEC File Number (Registration statement into which this 6-K is incorporated.)
Key Players & Entities
- Quantum Biopharma Ltd. (company) — Registrant
- FSD Pharma Inc. (company) — Former company name
- August 29, 2024 (date) — Date of press release
- August 30, 2024 (date) — Filing date
- 333-276264 (filing_id) — Form F-3 SEC File Number
- 001-39152 (filing_id) — SEC File Number for Quantum Biopharma Ltd.
FAQ
What is the specific title of the press release incorporated by reference?
The filing states the press release title is not fully provided in the excerpt, only that it was issued on August 29, 2024.
What is the purpose of incorporating this 6-K into the Form F-3 Registration Statement?
The filing states that the Form 6-K and Exhibit 99.1 are incorporated by reference into the Registrant's Registration Statement on Form F-3, suggesting it contains information relevant to the registration.
When did FSD Pharma Inc. change its name to Quantum Biopharma Ltd.?
The date of the name change from FSD Pharma Inc. to Quantum Biopharma Ltd. was March 27, 2019.
What is Quantum Biopharma Ltd.'s principal executive office address?
The principal executive office is located at 199 Bay St., Suite 4000, Toronto, Ontario M5L 1A9, Canada.
Does Quantum Biopharma Ltd. file annual reports under Form 20-F or Form 40-F?
Quantum Biopharma Ltd. files annual reports under Form 20-F, as indicated by the checkmark next to 'Form 20-F'.
Filing Stats: 264 words · 1 min read · ~1 pages · Grade level 9.9 · Accepted 2024-08-30 09:46:48
Filing Documents
- fsd_6k.htm (6-K) — 12KB
- fsd_ex991.htm (EX-99.1) — 18KB
- fsd_ex991img2.jpg (GRAPHIC) — 8KB
- 0001654954-24-011306.txt ( ) — 42KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Quantum BioPharma Ltd. (Registrant) Date: August 30, 2024 By: /s/ Nathan Coyle Nathan Coyle, Chief Financial Officer 3 EXHIBIT INDEX Exhibit Description Exhibit 99.1 Press Release dated August 30, 2024 – Quantum Biopharma announces Celly Nutrition Launches unbuzzd grab-and-go stick packs on Amazon.com so you can "own NOW and what's NEXT". 4